Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation by Hlushchuk, Ruslan et al.
Tumor Recovery by Angiogenic Switch from
Sprouting to Intussusceptive Angiogenesis after
Treatment with PTK787/ZK222584 or Ionizing
Radiation
Ruslan Hlushchuk,*¶ Oliver Riesterer,†
Oliver Baum,* Jeanette Wood,‡ Guenther Gruber,§
Martin Pruschy,† and Valentin Djonov*¶
From the Institute of Anatomy,* University of Bern, Bern,
Switzerland; Department of Radiation Oncology,† University
Hospital, Zurich, Switzerland; Novartis Pharma AG,‡ Basel,
Switzerland; Department of Radiation Oncology,§ University
Hospital, Bern, Switzerland; Institute of Anatomy,¶ University of
Fribourg, Fribourg, Switzerland
Inhibitors of angiogenesis and radiation induce com-
pensatory changes in the tumor vasculature both dur-
ing and after treatment cessation. To assess the re-
sponses to irradiation and vascular endothelial
growth factor-receptor tyrosine kinase inhibition (by
the vascular endothelial growth factor tyrosine kinase
inhibitor PTK787/ZK222854), mammary carcinoma
allografts were investigated by vascular casting; elec-
tron, light, and confocal microscopy; and immuno-
blotting. Irradiation and anti-angiogenic therapy had
similar effects on the tumor vasculature. Both treat-
ments reduced tumor vascularization, particularly in
the tumor medulla. After cessation of therapy, the
tumor vasculature expanded predominantly by intus-
susception with a plexus composed of enlarged sinu-
soidal-like vessels containing multiple transluminal
tissue pillars. Tumor revascularization originated
from preserved -smooth muscle actin-positive ves-
sels in the tumor cortex. Quantification revealed that
recovery was characterized by an angiogenic switch
from sprouting to intussusception. Up-regulated
-smooth muscle actin-expression during recovery
reflected the recruitment of -smooth muscle actin-
positive cells for intussusception as part of the angio-
adaptive mechanism. Tumor recovery was associated
with a dramatic decrease (by 30% to 40%) in the
intratumoral microvascular density, probably as a re-
sult of intussusceptive pruning and, surprisingly,
with only a minimal reduction of the total microvas-
cular (exchange) area. Therefore, the vascular supply
to the tumor was not severely compromised, as dem-
onstrated by hypoxia-inducible factor-1 expression.
Both irradiation and anti-angiogenic therapy cause a
switch from sprouting to intussusceptive angiogene-
sis, representing an escape mechanism and account-
ing for the development of resistance, as well as rapid
recovery, after cessation of therapy.
Tumor relapse and the development of drug resistance is
a major problem in the management of solid tumors. It
may be inherent to the tumor-cell compartment, to the
aberrant and inefficient vasculature, or to the surrounding
stroma. In the first case, a refractory subpopulation of
clonogenic cancer cells survives and proliferates. In the
second case, the potency of therapy is hampered due to
limited tumor perfusion. The tumor vasculature can be
damaged by chemotherapeutics, but interestingly, in
particular in response to inhibitors of angiogenesis, the
tumor vasculature may undergo morphological changes
that normalize the tumor vasculature. This tumor vascular
normalization concept claims that treatment with low
doses of angiogenesis inhibitors preferentially targets im-
mature vessels and thereby creates a normalization of
the blood vessel with improved functionality and results in
better perfusion of the remaining tumor mass.1 This could
diminish tumor hypoxia by improved delivery of oxygen
and also improve the delivery of chemotherapeutics.
The administration of anti-angiogenic agents is now gen-
erally recognized as a promising therapeutic approach in
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the management of cancer patients.2–5 During the past few
years, many such drugs have been developed to target
various steps in pathological vascularization, including
cytokine-induced stimulation and integrin-mediated mi-
gration of vascular endothelial cells and enzymatic deg-
radation of extracellular matrix components.6,7
Vascular endothelial growth factor (VEGF) is an ex-
tremely potent pro-angiogenic factor, which is involved in
both physiological and pathological vascular growth.
Many human neoplasms and animal tumor models ex-
press high mRNA and protein levels of VEGF.2,8,9 Inhibi-
tion of VEGF or of its receptors should block the down-
stream cascade and interfere with its pro-angiogenic
effects and thereby block tumor vascularization.
Bevacizumab, a humanized monoclonal antibody against
VEGF, has validated this therapeutic approach in patients
with various types of cancers. Its application, either alone
or in combination with chemotherapy, has led to a signif-
icant increase in the survival rate of patients with meta-
static colorectal cancer and other cancers.10–12
An alternative therapeutic strategy involves the suppres-
sion of VEGF signaling pathways. Indeed, tyrosine-kinase
inhibitors of the VEGF receptors have been recently used as
anti-angiogenic agents against pathological neovascular-
ization and have even undergone early clinical evalua-
tion.13,14 Most of the agents, for example, Bay-43–9006
(Nexavar) or SU11248 (Sutent) are broad spectrum ty-
rosine-kinase inhibitors. PTK787/ZK22854 (PTK/ZK) (Vata-
lanib) (Novartis Pharma AG, Basel, Switzerland) is one of
the most selective inhibitors of VEGFR-1, VEGFR-2, and
VEGFR-3, which can be administered orally. Its dose-de-
pendent anti-angiogenic effects and efficacy have been
well documented, both in animal models and in human
patients.15–19
Treatment response to radiotherapy is partly deter-
mined by sensitivity of the tumor vasculature to radiation.
Studies show that endothelial apoptosis determines radi-
ation response in murine tumor models.20,21 In addition
clinical studies show that an angiogenic response, as
indicated by changes in microvessel density after radio-
therapy, significantly correlate with response to radiation
and survival.22,23 A reduction in tumor vascularization
would be expected to increase resistance of tumor cells
to irradiation since tumor cells irradiated in normoxic
conditions are 2 to 3 times more radiosensitive than cells
irradiated under severe hypoxia. However, anti-VEGF/
VEGFR strategies enhance, rather than reduce the ef-
fects of fractionated radiation.24 Tumor re-oxygenation as
part of vascular response to anti-angiogenic therapy could
be a mechanism of the increased sensitivity of tumors to
ionizing radiation after anti-angiogenic therapy. Thus it is
important to understand morphological changes of the tu-
mor vasculature after either radio or anti-angiogenic therapy
in more detail.
Vascular morphological alterations by means of intus-
susceptive angiogenesis have been observed in hepato-
cellular carcinoma model during treatment with sirolimus,
a mTOR inhibitor.25 Treated rats had significantly longer
survival, developed smaller tumors and fewer extrahe-
patic metastases. During the treatment and during the
early recovery phase vascular sprouting was absent,
whereas intussusception was observed. Intussusceptive
angiogenesis has been extensively described in the last
decade during normal development and growth [for more
details see reviews26,27]. Intussusception, ie, the forma-
tion of transluminal tissue pillars, represents an alterna-
tive to the sprouting mode of angiogenesis. It is an im-
portant mechanism of capillary growth, formation of small
arteries and veins, vascular pruning and angio-adaptive
remodeling. Intussusception is associated with alter-
ations in hemodynamic conditions and acts only in pre-
existing vasculature.
The advantages of this latter mechanism of growth
over sprouting are that: (i) blood vessels are generated
more rapidly; (ii) it is energetically and metabolically more
economic, since extensive proliferation of endothelial
cells, degradation of the basement membrane and inva-
sion of the surrounding tissue are probably not required;
and (iii) the capillaries thereby formed are less leaky.26,27
Vascular growth and remodeling by intussusception oc-
cur without disrupting of the organ function, which is
essential during both embryonic development and post-
natal life.
In the present study, we investigated the adaptive
response of the tumor vasculature to a highly selective
inhibitor of angiogenesis and to ionizing radiation and
identified an angiogenic switch from sprouting to intus-
susceptive angiogenesis as novel mechanism to coun-
teract the antivascular effects of both of these treatment
modalities.
Materials and Methods
Tumor Xenografts in Nude Mice and the
Administration of PTK/ZK or Radiotherapy
MMTV/c-neu murine carcinoma cells (4  106) were in-
jected subcutaneously into the flank of 4- to 8-week-old
athymic nude mice. Tumor volumes were determined
from caliper measurements of tumor length (L) and width
(l) according to the formula (L  l2)/2. Tumors were
allowed to expand to a volume of minimally 200 mm3
(diameter 7 mm) before treatment. Measurement of
“volume Tu necrosis/entire Tu volume” ratio has been
performed according to the Cavalieri’s principle.28
PTK787/ZK222584 (dissolved in water containing 5% di-
methyl sulfoxide and 1% Tween-80) was administered
orally at a dose of 100 mg/kg of body weight on 4 con-
secutive days. Mice subjected to radiotherapy received a
daily dose of 3 Gy, likewise for 4 consecutive days. The
tumors from control and both treated groups (altogether
n  90: n  6 to 8 per time point and per group) were
harvested on days 5, 9, 14, and 19 after the onset of
treatment: 3 to 4 tumors for vascular casts and another 3
to 4 for paraffin and transmission electron microscopy
sections and immunoblotting. All numerical data were
statistically analyzed using the Mann-Whitney U-test. The
animal experiments were conducted in accord with UKC-
CCR guidelines.29
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-Smooth Muscle Actin Immunoblotting
After solubilizing the tissue, 50-g aliquots of the pro-
tein extracts were subjected to SDS-polyacrylamide
gel electrophoresis on 10% gels under reducing con-
ditions. The gels were transferred to nitrocellulose
membranes (Schleicher and Schuell, Dassel, Ger-
many) and treated with 5% (w/v) milk powder. They
were then incubated overnight with antibodies specific
for -smooth muscle actin (SMA) [(Sigma, Buchs, Swit-
zerland) diluted 1:5000]. Thereafter, they were treated
for one hour with the corresponding peroxidase-conju-
gated secondary antibody (Sigma, Buchs, Switzer-
land). Bound antibodies were detected by chemolumi-
nescence using an enhanced chemiluminescence
detection kit (Supersignal, Pierce, Rockford, IL).
Vascular Casting, Morphology, and
Morphometric Analysis
Vascular casts were prepared as previously described.30
Briefly, the systemic or local vasculature was perfused
with a freshly prepared solution of Mercox (Vilene Com-
pany, Japan) containing 0.1 ml of accelerator per 5 ml of
resin. One hour after perfusion, the tumors were excised
and transferred to 7.5% potassium hydroxide for the dis-
solution of tissue, which was effected over a course of 3
to 4 weeks.
For the further morphometric analysis the vascular
casts were then frozen in water and bisected through the
tumor center. Thereafter the casts were dried and glued
onto aluminum stabs, sputtered with gold, and examined
in a Philips XL-30 FEG scanning electron microscope.
The positions for the quantitative evaluation (at least 10
per sample) were chosen using systematic uniform ran-
dom sampling scheme.31 Using this random technique
there were some partially or almost “empty” fields corre-
sponding to the necrotic areas in the tumor. Such fields
have not been excluded from the analysis, but this was
the reason why we have used such a parameter as
numerical density per vessel area but not per field of
view. This allowed us to consider all of the fields regard-
less of the grade of their “emptiness.” Pillars were iden-
tified as holes in vascular casts whose diameter roughly
measured less or equal to 2.5 m. All holes greater than
2.5 m normally referred to as meshes were ignored.
Capillary sprouts were identified as tapered blind ending
capillary branches without visible cut surface at its end
and whose average diameter was less than 4 m. The
quantification technique used here has been described
in detail by Makanya et al.32
Immunostaining for CD31 and SMA and Its
Evaluation
For immunohistochemical evaluation 3-m-thick paraffin
sections of the tumors were processed according to Ma-
kanya et al.32 The first antibodies diluted in Tris-buffered
saline: mouse anti-CD31, diluted 1:20 (M-0823, clone
JC/70A; Dako, Glostrup, Denmark); and mouse anti-SMA,
diluted 1:200 (Sigma, Buchs, Switzerland). The analySIS
Software 3.2 (Soft Imaging System, Munich, Germany)
was used for estimation of intratumoral microvascular
density and vascular area density. The pictures used for
quantification were taken from vascular “hot spots” at
200 magnification (at least four “hot spots” per tumor):
after the inspection of a CD31-stained section through
the tumor center the investigator picked up and took
images of 6 to 8 fields of view with seemingly highest
number of vessels. Afterward, the number of vessels was
determined in each of the taken images and the four with
the highest vessel count were considered for further anal-
ysis. If more than one image had the fourth highest vessel
count, all of the images with this count were also consid-
ered for further analysis. The number of vessels per field
of view was counted by the investigator by pointing
(clicking) at each individual vessel in the images ob-
tained and the mentioned software simply counted the
number of “points.” The vascular area density was cal-
culated by overlaying the grid with 96 crossings points
over the image. The number of crossing points that ap-
peared to lie over the vessels was counted in the similar
way as number of vessels (investigator-driven). The ratio
between the obtained number and the total number of
points in the overlay grid was the vessel area density.
Laser Scanning Microscopy and CD31-SMA
Double Immunostaining
Sixty-m-thick paraffin sections were pretreated accord-
ing to Makanya et al.32 In a second step they were
incubated with the first antibody anti-CD31 (CD31
MEC13.3 [rat]), diluted 1:100 in Tris-buffered saline, then
washed and incubated with mouse anti-SMA, diluted
1:200 (Sigma, Buchs, Switzerland). Sections were ex-
posed to a second goat anti-rat antibody coupled with
CyTM3 (Jackson ImmunoResearch Laboratories, Inc.,
PA) diluted 1:200 in Tris-buffered saline for 60 minutes at
ambient temperature, washed, and then incubated with
anti-mouse antibody coupled with fluorescein isothiocya-
nate for a similar period at the same temperature. The
sections were then washed, mounted with Mowiol, and
examined using a Zeiss LSM 510 Meta confocal micro-
scope (Axiovert 200M), which was equipped with HeNe
(633 nm), HeNe (543 nm), and Ar (488 nm) lasers. Three-
dimensional, multichannel image-processing software
(IMARIS, Bitplane AG, Zurich, Switzerland) was used to
process the obtained microscopic images.
Transmission Electron Microscopy
Tumor samples were harvested and processed as de-
scribed in Djonov et al.33 They were stained with lead
citrate and uranyl acetate before viewing in a Philips
EM-400 transmission electron microscope.
5-Bromo-2-Deoxyuridine Staining
Three hours before sacrifice the mice whose tumors were
to be harvested for the paraffin sectioning were injected
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intraperitoneally with 0.3 ml of a 20 mg/ml 5-bromo-2-
deoxyuridine (BrdU) solution. For BrdU staining, 3-m-
thick paraffin sections of the harvested tumors were pro-
cessed according to Birner et al.34 The primary antibody
used: mouse anti-BrdU, diluted 1:100 (B-2531, Sigma,
Buchs, Switzerland). Detection of anti-BrdU binding was
performed using an avidin-peroxidase system (A-3151;
Sigma, Buchs, Switzerland).
Hypoxia-Inducible Factor-1 Immunostaining
For hypoxia-inducible factor (HIF)-1 staining, 3-m-
thick paraffin sections of the harvested tumors were pro-
cessed according to Gruber et al.35 The primary antibody
used was monoclonal antibody H1a67 (Novus Biologi-
cals, Littleton, CO) diluted 1:5000 for 30 minutes at am-
bient temperature. The biotinyl tyramide amplification re-
agent was diluted 1:10 in protein blocking solution (Dako,
Carpinteria, CA).
Results
PTK/ZK and Radiation Inhibit Tumor Growth
and Induce Central Necrosis
Mice bearing xenografts derived from c-neu-overex-
pressing murine mammary adenocarcinoma cells were
treated on 4 consecutive days with the VEGF-receptor
tyrosine-kinase inhibitor PTK/ZK (4  100 mg/kg) or with
ionizing radiation (4  3 Gy). To determine the time
course of tumor growth- and treatment-dependent tumor
necrosis the size of tumors were determined by caliper
measurements and tumors from the different treatment
groups were harvested on days 5, 9, 14, and 19 after the
onset of treatment. The growth inhibitory effect was sta-
tistically significant (P  0.02) for both treatment groups
at day 14 and at days 9 and 19 for radiation treatment
(Figure 1A). On days 9 and 14, central necrosis em-
braced a larger relative volume in both treatment groups
than in the control animals (Figure 1B). In the both treat-
ment groups, casts of the tumor vasculature revealed the
medullary plexus to be completely destroyed. A large
central avascular area was apparent, and this probably
corresponded to the necrotic region (Figure 1C). The
time courses of the changes were different after anti-
angiogenic and radiotherapy (Figure 1B). In the mice that
were treated with PTK/ZK or radiation, central necrosis on
day 9 was significantly greater than in the control tumors.
On day 19 there was no difference between tumors from
PTK/ZK treated mice or control mice, whereas tumors
from mice treated with radiation showed less central ne-
crosis on day 19. After either treatment, cortical vessels
and larger medullary vessels remained perfused on day
9 and had pillars and meshes, signs of ongoing intussus-
Figure 1. The graph (A) and bar graph (B) showing tumor growth delay and central necrosis. A, B: PTK/ZK and radiation delayed tumor growth (A) and induced
central necrosis (estimated as a ratio “volume tumor necrosis/entire tumor volume”) (B). Mean values (n 3) are represented together with the SD. *Value is
significantly different from the control (*P  0.02). Tumor growth was inhibited by both treatment strategies. C, C: Vascular casts of MMTV/c-neu mammary
carcinoma xenografts, on day 5 (C) and day 9 (C) after onset of treatment with PTK/ZK. Large avascular areas (asterisks) are apparent within the medullary
region. Multiple tiny capillary sprouts emanate from the preserved cortical vessels and invade the avascular medulla (arrowheads). D–F: Transmission electron
micrographs illustrating changes in the vessels. In (D), a vessel in a non-treated tumor with intact endothelium is shown. E, F: Attenuation with partial denudation
(see inserts) and vacuolization (asterisks) of endothelial cells in the tumor vessels after treatment with PTK/ZK (E) or irradiation (F). The magnification is 3600;
the scale bar is presented in (D).
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ception. Many tiny capillary sprouts emanated from the
preserved cortical vessels and invaded the avascular
medulla (Figure 1C). At the ultrastructural level the at-
tenuation with partial denudation and vacuolization of
endothelial cells in the vasculature of treated tumors on
day 5 (Figure 1, E and F) was evident. In the non-treated
tumors the endothelium was intact (Figure 1D).
The Survival of Cortical Vessels Is Linked to the
Presence of SMA-Positive Cells
One day after the cessation of treatment with PTK/ZK (day
5), the medullary capillary plexus was completely de-
stroyed. The functionally preserved cortical region usually
occupied a breadth of 0.5 to 1 mm (Figure 1, C–C). In
untreated tumors (Figure 2, A–C), the tumor cortex was well
supplied with small vessels that bore a covering of SMA-
positive cells (Figure 2, B–B). In contrast, microvessels
located within the medulla were generally SMA-negative
(Figure 2, C–C). This spatial distribution revealed by immu-
nohistochemistry corresponded to the pattern revealed by
immunoblotting for SMA (Figure 2D) and reflected the stage
of vascular maturation. Combined with the aforementioned
preservation of mainly cortical or larger medullary vessels,
these results indicate that the anti-angiogenic effects of
radiotherapy or PTK/ZK were confined to the immature ves-
sels, which were located in the medulla. The more mature
cortical vessels with a peri-endothelial covering were resis-
tant to both treatment modalities.
Revascularization and Recovery of the Tumor
Stem from SMA-Positive Vessels in the Cortex
To determine whether revascularization and recovery of
the tumor originates from SMA-positive vessels in the
cortex, the proliferative capacity was determined in re-
sponse to radiation therapy or PTK/ZK treatment using
BrdU-immunostaining. From day 5 onwards, tumors un-
derwent revascularization and recovery. On day 5, an
obvious difference in the number of proliferating cells
was observed between the cortex and the medulla in
both treatment groups (Figure 3, A–B). The proliferating
cells were detected mainly in periphery of the tumor.
Thereafter the overall proliferative rate of tumor cells in-
creased and the difference between cortex and medulla
diminished (Figure 3C). Quantification of the number of
proliferating tumor cells within the cortical and the med-
ullary regions disclosed a rapid recovery in the PTK/ZK-
treated group and a slower one in the animals that had
undergone radiotherapy, indicative for a stronger antipro-
liferative effect of radiation than for PTK/ZK (Figure 3B).
Proliferative activity correlated positively with tumor vol-
ume and negatively with the relative volume of central
necrosis (Figure 1, A–B).
Tumor Recovery Is Associated with
Intussusceptive Microvascular Growth
Besides formation of capillary sprouts originating from
the cortical plexus, first augmentations of intussuscep-
tive angiogenesis were observed immediately after
cessation of therapy in the PTK/ZK-treated tumors.
Between day 9 and 14, the vasculature in both treated
groups expanded predominantly by intussusception: the
intratumoral plexus consisted of large sinusoidal vessels
and casts of the vessels revealed the presence of numer-
ous tiny holes, the hallmarks of intussusceptive angio-
genesis (Figure 4, D, F). These holes represented trans-
luminal tissue pillars, which were digested during the
process of maceration. Quantification of the number of
newly formed pillars (with a diameter of less than 2.5 m)
per vascular area on day 9 revealed a significant in-
crease in both treatment groups (Figure 4G). By day 19,
intussusception had given way to a second wave of
sprouting angiogenesis (Figure 4H). At this latter junc-
ture, the ratio of sprouts to pillars in the PTK/ZK-treated
group was similar to that in the control mice. In the tumors
that had undergone radiotherapy, the sprout numerical
density was significantly higher, indicating an even more
pronounced stress response.
The Specific Time-Course of the Changes in the
Vascular Pattern of Treated Tumors
The vascular pattern of the non-treated tumors was char-
acterized mainly by sprouting mode of angiogenesis (see
Figure 4B). As shown in Figure 5A, the vascular pattern of
the treated tumors had its specific time-course: the signs
of intussusception were prevalent on day 6 (Figure 5A)
and day 14 (Figure 5A). Noteworthy, that on day 6 there
were not only pillars, but also meshes apparent (Figure
5A). The appearance of the meshes needs a relatively
longer time; therefore the intussusception had been ac-
tivated already by the end of the treatment if not during it.
On day 19 the vascular pattern was characterized by
numerous sprouts (arrows in Figure 5A) with still present
but fewer signs of intussusception indicating the second
wave of sprouting.
The scheme in Figure 5B presents the time-course
specific changes in the angiogenesis mode (switch
sprouting to intussusception) after the therapy cessation
in comparison with non-treated tumors.
Tumor Recovery Is Associated with a Dramatic
Decrease in Intratumoral Microvascular Density,
but with Only a Non-Significant One in the
Vascular Exchange Surface
Intratumoral microvascular density (IMD) is widely used
as a gauge of tumor behavior. A high IMD, being equated
with high metabolic activity, is presumed to forebode an
unfavorable prognosis and outcome. Vessel area density
(VAD), also defined as total microvascular area,36 is a
parameter representing more directly the blood supply
and in this way probably better correlates with the trans-
endothelial transport of nutrients and oxygen, and thus
with the vasculature-related metastatic potential of the
neoplasm.
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Figure 2. Consecutive sections through MMTV/c-
neu mammary carcinoma xenografts showing im-
munostaining for CD31 (A, B, C) and SMA (A, B,
C). Multiple vessels within the cortex (arrowheads
in B) bear a covering of SMA-positive cells (arrow
in B), whereas those within the medulla (arrow-
heads in C) are mainly SMA-negative (positive is
marked with arrow in C). The spatial distribution
of SMA accords with the distribution revealed by
immunoblotting (D). Scale bars  200 m (A, A)
and 50 m (B, B, C, C) presented in the right lower
corner of (A) and (C) accordingly.
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The CD31-immunostaining revealed qualitative differ-
ences in the vascular pattern of different groups (Figure
6A–C). The subsequent quantification demonstrated the
decrease of the IMD in both treated and of the VAD in the
irradiated group on day 5 (Figure 6D). On day 9 the IMD
was still decreased by more than 40% in the PTK/ZK-
treated group and by more than 30% in the irradiated
tumors. In contrast, the VAD was only slightly lower at this
juncture (Figure 6E). By day 19, the IMD was increased in
each of the treated groups, whereas the VAD remained
unchanged (Figure 6F). The differential effect on IMD and
VAD mirrors the onset of the treatment-induced intussus-
ception; intussusceptive angiogenesis leads to the stretch-
ing of the endothelium and formation of large, sinusoidal
vessels. This phenomenon counterbalanced the de-
crease of the IMD, thus enabling the tumor vasculature
to maintain its functional capacity (ie, without compro-
mising the VAD).
The HIF-1 staining of the tumor samples harvested on
day 14 has corroborated the finding that the functional
capacity of the vasculature was adequately maintained
(Figure 6, G–I). In the control tumor there were HIF-1-
positive cells at in the typical arrangement surrounding
the microvessels (Figure 6G); in both treated groups
there was no such pattern revealed the tumor cells were
mainly HIF-1-negative (Figure 6, G–I). The blood supply
to the tumor cells in treated groups appeared to be yet
improved in the recovery period if compared with the
control group.
Tumor Recovery Is Associated with
Up-Regulation of SMA
One of the crucial steps of intussusception is invasion of
interstitial pillar cores with pericytes, SMA-positive cells
and myofibroblasts, which lay down collagen fibrils. By
this stage, the transluminal pillars have a diameter of less
than 2.5 m. In the subsequent phase, the pillars in-
crease in girth by additional recruitment of peri-endothe-
Figure 3. Proliferative activity of tumor cells on day 5 visualized by BrdU immunostaining revealed treatment-specific spatial tumor recovery (A). The outer “ring”
of the tumor with the breadth of up to 1 mm was characterized by the maximal proliferating activity. The counting of BrdU-positive cells on days 5 and 14 indicated
a specific time-course of tumor recovery (B). On day 14 the overall proliferative rate of tumor cells increased and the difference between cortex and medulla
diminished (C). The values significantly different from control values are marked with *(P  0.02) or #(P  0.05).
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Figure 4. A–F: Vascular casts of MMTV/c-neu mammary carcinoma xenografts on day 14 revealing a change in the mode of vascular growth from sprouting (in
control animals) to intussusception (after treatment with PTK/ZK or irradiation). The revascularization process involves mainly intussusceptive angiogenesis, as
evidenced by the presence of numerous tiny holes in the casts (arrows). In the control tumors, vascular growth occurs predominantly by sprouting
(arrowheads). G, H: Bar graphs showing the number of newly-formed pillars (with a diameter of less than 2.5 m) and sprouts per vascular surface on days
9 (G) and 19 (H). The values significantly different from control values are marked with *(P  0.02) or #(P  0.05).
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lial cells and deposition of extracellular matrix proteins,
without undergoing any further change in their structure.
The so-formed large pillars (termed also meshes) are
robust structures that are unlikely to regress.
The light and laser scanning confocal microscopy re-
vealed numerous SMA-positive cells to be located not
only in the vicinity of the pillars (Figure 7, A), but also as
a robust multilayered peri-endothelial covering (Figure 7,
B–B). SMA-immunoblotting disclosed higher levels in
the medulla than in the cortical region of tumors on day 9
(Figure 7C). This finding indicates that during the process
of tumor recovery adaptive changes were triggered in the
medullary vessels.
Discussion
The recovery of tumors after therapy is a major problem in
the management of cancer patients. The regrowth of
neoplasms after cytotoxic treatment is attributable to the
proliferation of a subpopulation of treatment resistant,
often hypoxic tumor cells.37 Tumor angiogenesis is gen-
erally deemed to be crucial for the growth and dissemi-
nation of tumors, which is the rationale for the application
of angiogenesis inhibitors as cancer therapy. A broad
spectrum of such agents (mainly VEGF inhibitors) have
been tested on the preclinical and clinical level.6,7,14
Even though angiogenesis inhibitors induce a partial re-
gression of tumor vessels and elicit a reduction in tumor
size, the effects are transient and long-term results are
disappointing.15,38–40 During tumor recovery remodeling
of blood vessels in conjunction with the proliferation of
tumor cells might be part of adaptive mechanisms that
allow recovery of the tumor and contribute to the devel-
opment of resistance to therapy.
In our report we suggest that a window of intussuscep-
tion after angiogenesis inhibition occurs as an adaptive
mechanism to restore and maintain vascular function
after treatment related damage. The detailed analysis of
the morphological changes demonstrates a switch from
sprouting to intussusceptive angiogenesis, which occurs
not only after treatment cessation with this inhibitor of
angiogenesis but also during the recovery period from
fractionated irradiation. After exposure to PTK/ZK or ion-
izing radiation, the sinusoidal-like vessels were charac-
terized by numerous transluminal tissue pillars. These
pillars are hallmarks of intussusceptive angiogenesis. Of
note, intussusceptive angiogenesis after treatment with
PTK/ZK has already been documented (albeit unbe-
Figure 5. Micrographs and schema illustrating time-course of the angiogenic switch during tumor recovery. The scanning electron micrographs representing the
vascular pattern of the PTK/ZK treated tumors on day 6 (A), 14 (A), and 19 (A). On day 6 and 14 pillars (arrowheads) and meshes (asterisks) dominate. In
contrast to days 6 and 14, on day 19 (A) the sprouts (arrows) prevail in the vascular pattern of the PTK/ZK-treated tumors with some pillars (arrowhead) or
meshes (asterisks) present. The bar in (A–A) is 100 m. The scheme in B represents the above-described changes: in non-treated tumors the dominating mode
of angiogenesis is sprouting. After the short-term therapy the intussusception prevails: so called, intussusceptive phase of recovery (days 6, 9, and 14). On day
19 the second wave of intussusception is there what is characterized by numerous sprouts along with pillars or meshes.
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known to the authors) in other tumor models, such as in a
murine renal cell carcinoma study including treatment
with PTK/ZK.19 In this study PTK/ZK elicited changes in
the vasculature that are typical of intussusception,
namely, the appearance of large sinusoidal-like vessels
and an increase in the intervascular distance. On the
other hand the vessel density decreased by as much as
48%, and the systolic blood-flow velocity in the renal
artery remained unchanged. The relative tumor blood
volume increased by 44%, and the vessel permeability
decreased by 50%.19 Furthermore, although the demon-
strated vascular casts clearly revealed the presence of
transluminal pillars, the authors did not recognize the
phenomenon of intussusceptive angiogenesis. Similar
morphological and hemodynamic changes in the vascu-
lature have been observed in murine orthotopic B16/BL6
melanoma tumor model after treatment with either PTK/
ZK41 or other tyrosine kinase inhibitors, such as
KRN951,42 CEP-7055,43 and KRN633.44 In each in-
stance, the described changes in the vessels correspond
to those associated with intussusceptive angiogenesis.
Intussusceptive angiogenesis might represent a general
process as part of a tumor-protective adaptive response.
A switch from sprouting to intussusceptive angiogen-
esis might represent an adaptive response to treatment
with various anti-tumor and anti-angiogenic compounds.
Exposure of rat hepatic carcinomas to sirolimus (an
mTOR-kinase inhibitor with anti-proliferative and anti-an-
giogenic properties) impaired tube formation and the
vascular sprouting of aortic rings in vitro.25 Furthermore,
the surviving vessels in SK-NEP-1 tumor xenografts in
mice after treatment with VEGF-Trap, were sinusoidal-like
and centrally located in the viable and growing tumor
regions. These vessels bore a coverage of SMA-positive
peri-endothelial cells.45 Likewise, tumor recovery after
treatment with AG-013736 or AG-028262 (inhibitors of
VEGF-receptor signaling) in the RIP-Tag 2 and Lewis
lung carcinoma models was associated not only with
rapid revascularization with the denuded sleeves of
basement membrane serving as a scaffold: the high-
quality images also demonstrated definite evidence of
intussusceptive angiogenesis.46
Figure 6. A–C: Immunohistochemical staining of MMTV/c-neu mammary carcinoma xenografts for CD31 revealing a multitude of tiny vessels in control tumors
and fewer, but larger sinusoidal ones in the treated groups. D–F: Changes in the IMD; number of vessels per 200 field of view) and vessel area density on days
5, 9, and 19 reflect a switch in the mode of angiogenesis: intussusception on day 9 and a second wave of sprouting on day 19. The values significantly different
from control values are marked with *(P  0.02) or #(P  0.05). The HIF-1 staining (G–I) reveals the differences in oxygenation level of the tumor cells on day
14: in non-treated tumors (G) there is apparent hypoxia demonstrated by plentiful HIF-1-positive cells on the distance of more than 100 to 130 m from the
vessels (arrowheads in G–I). There are necrotic areas on similar distances from the vessels (asterisks in G). On day 14 in both treated groups the level of
oxygenation is apparently better with only some HIF-1-positive cells (H and I). The vessels are marked with arrowheads (G–I). The magnification is 200.ht
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In primary human tumors, as well as in murine tumor
models, inhibition of VEGF/VEGFR signaling induces se-
lective apoptosis of endothelial cells in immature capil-
laries. In contrast, mature vessels with a coverage of
peri-endothelial cells survive VEGF withdrawal.47 In a
recent publication, treatment with PTK/ZK in the B16/BL6
melanoma tumor model induced a significant decrease in
vessel density within cervical metastases but not within
primary tumors.41 These findings most probably reflect
the relative immaturity of the vascular plexus in metasta-
ses compared to the vasculature in the primary tumor.
Our own recent data on nonmalignant vessels in the
developing chorioallantoic membrane of the chicken also
demonstrated that exposure to PTK/ZK induced signifi-
cant regression of the vasculature on embryonic day 8,
but had no effect on day 12, a stage at which microves-
sels are already covered with pericytes.48
In the present study transmission electron microscopy
data revealed that exposure of the tumors to PTK/ZK or
ionizing radiation led to attenuation with partial denuda-
tion and vacuolization of endothelial cells in the tumor
vessels and subsequent instability of the vessel walls. In
another ongoing study we have observed by epifluores-
cence microscopy after injection of fluorescein isothio-
cyanate-dextran solution that irradiation induces focally
increased permeability of vessels. Electron microscopy
has revealed that the irradiated vasculature has the same
morphological alterations as presented here for the tumor
vessels of both treatment groups. These findings suggest
that the morphological changes after irradiation are ubiq-
uitous. The described changes in the vasculature and its
altered permeability explain the frequent occurrence of
extravasates in the vascular casts of tumors immediately
after the treatment cessation (day 5, data not shown),
which prevented quantification of the casts at this time
point. In contrast, the occurrence of extravasates had no
crucial influence on the quality of the vascular casts
made on days 9, 14, and 19. Such time-course indicates
that by day 9 the tumoral vascular tree had undergone
substantial remodeling, presumably by vascular pruning.
The signs of intussusception are already seen on day 6,
as demonstrated in Figure 5A. Therefore, the angiogenic
switch to intussusception probably takes place already
during the therapy or immediately after its cessation.
Moreover, we observed that exposure to PTK/ZK or ion-
izing radiation destroyed mainly the immature medullary
vascular plexus while cortical vessels, which bear a cov-
erage of SMA-positive cells, remained perfused. Tumor
recovery originated from the morphologically and func-
tionally preserved cortical region with the number of pro-
liferating tumor cells decreasing progressively from the
cortical to the medullary region, in accord with a de-
crease in the density of the vessels.
Following cessation of treatment, the inhibitory effects
of PTK/ZK and ionizing radiation on tumor growth abated
after about one week. Tumor regrowth coincides with the
second wave of sprouting angiogenesis. A transient
switch from sprouting to intussusceptive angiogenesis
may be an adaptive response to restore the hemody-
namic and structural properties of the vasculature (see
scheme in Figure 5B). Intussusceptive remodeling and
probably pruning accompanied by the recruitment of
SMA-positive cells restores the tumor vasculature. This is
characterized by a low rate of endothelial proliferation
and by low transendothelial permeability. In this study the
HIF-1-staining clearly represents the sufficient oxygen
Figure 7. Spatial distribution of SMA on day 9. A, B: Laser scanning microscopy (A) of double-immunostaining [CD31-red (endothelium); SMA-green
(SMA-positive cells)] and light microscopic inspection of toluidine-blue-stained consecutive sections (B–B) revealed that SMA-positive cells are located in the
vicinity of pillars (arrows in A and B) and also as peri-endothelial covering (arrowheads in A and B). The double arrows in A and B indicate transluminar tissue
pillars. C: Estimation of SMA by immunoblotting revealed higher levels in the medullary than in the cortical tumor regions. (C  cortex, M  medulla).
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supply to the tumor cells 10 days after the treatment
cessation. Moreover, using high resolution small animal
positron emission tomography in a mouse mammary can-
cer allograft model, we recently demonstrated that the
same schedule of PTK/ZK treatment resulted in en-
hanced tumor hypoxia by the end of treatment, but re-
oxygenation was again prevalent by day 14 (10 days
after treatment cessation).49 The angiogenic switch from
sprouting to intussusception in response to inhibition of
angiogenesis represents a part of angio-adaptive mech-
anism that most probably serves to repair a damaged
tumor vasculature to restore the oxygen supply to the
tumor.
Overall, our data indicate that an angiogenic switch
from sprouting to intussusceptive angiogenesis occurs
after treatment with the angiogenesis inhibitor or radiation
and may be part of a tumor-protective adaptive re-
sponse. In addition, the radiation-induced vascular dam-
age observed supports the concept that tumor vascula-
ture is one of the prime targets for radiation.
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